.png){kind=small}
Miro studied Bioengineering at Imperial College London and did research in systems and synthetic biology at Imperial College, Caltech, and Stanford during his undergraduate studies. Miro worked with TechBio VC investors in the US and Europe and consulted to public institutions and private enterprises in Central and Eastern Europe on life science R&D and business development. He was a graduate research affiliate at Stanford University, where he worked on synthetic biology-associated biosecurity matters. He advised to the Slovak Ministry of Health and Executive Board Member of the World Health Organisation on biosecurity and innovation. Miro is a Co-Managing Director of Nucleate United Kingdom, the world’s largest non-profit organisation supporting student-led life science enterprises. He is also in the final stages of his PhD in Engineering and Synthetic Biology at the University of Oxford.
Marian has a PhD in Molecular Biology at Oxford, where he focused on genetic engineering and cancer. He has more than 9 years of full-time wet-lab experience with cellular engineering. He worked at the top European research centres (including the University of Oxford, University of Gothenburg and Vienna BioCenter).
Paul has clinical and scientific expertise in transplant and heart failure, having published over 200 peer-reviewed scientific articles. He has been a serial entrepreneur and founder and Chief Medical Officer of medical device start-up companies, including Ardian; CHF Solutions; ARTritech Med; ROX Med and Advanced Heuristics. Paul has extensive executive experience: he served as a Medical Advisor to Medtronic and Merck Pharmaceutical, and as Entrepreneur-in-Residence at the White House, assigned to the FDA. Paul was a Professor of Medicine and Physiology at The Ohio State University, Loyola and Vice Chair of Medicine at Wayne State University.
Anton is a world-leading expert on mRNA production. Anton spent 10 years at TriLink BioTechnologies, a global leader in mRNA contract manufacturing, where he led the development of numerous techniques that were crucial for the successful commercial In Vitro Transcription-based mRNA production at gram scales. Previously he was an Assistant Professor at the University of Iowa School of Medicine. He received a B.A. in Molecular and Cellular Biology from UC San Diego, a Ph.D. in Chemistry and Biochemistry from the University of Colorado, Boulder and completed his postdoctoral fellowship at the Stanford University School of Medicine.
Leanne has worked in nucleic acid therapeutics for over 12 years including the Pfizer/BioNTech COVID vaccine and with adenoviral vectors. She has experience in both research and later-stage projects including designing RNA-lipid nanoparticle products along with GMP-compliant production processes. Leanne has expertise in the fundamental chemistry of both nucleic acid-based drug products, virus-like particles, and lipid nanoparticles. She also works to help direct R&D and strategy at the non-profit, AI-lead, antibiotic developer Phare Bio in collaboration with MIT. Leanne read Chemical Biology for her D.Phil. at Oxford University before conducting postdoctoral positions in HIV vaccine design, T-cell therapies, and hydrogel drug delivery technologies.
Michal completed Philosophy, Politics and Economics at Oxford in the top 10% of his class. Alongside leading operations at Sensible Bio, he is currently completing an MSc in Computing at Imperial College London, which is focused on applications of deep learning for the design of mRNA therapeutics. Previously, he worked as a Business Analyst intern at McKinsey and in a London-based Private Equity and Debt fund. He also worked in the Office of the President of the Slovak Republic.
Kelvin holds a PhD in Biochemistry from the University of Oxford, where he received a Clarendon Scholarship. Previously, Kelvin received his undergraduate degree in Biochemistry and Molecular Biology at the University of Melbourne and he worked as a scientist at Kalbe Farma, the largest publicly-listed pharma company in South Asia. Kelvin has more than 10 years of commercial and academic experience in genetic engineering and bioprocess quality control.
Liudmyla graduated from Taras Shevchenko National University in Kyiv. She holds a PhD in Molecular Biology and she did her doctoral studies at the Cell Signaling Department of the Institute of Molecular Biology and Genetics, National Academy of Science of Ukraine. Liudmyla co-authored 11 papers and presented at 8 conferences. Besides her extensive academic experience that spans more than 15 years, Liudmyla has more than 6 years of industrial experience working in the private biotech and pharma sectors in both startups (MultiplexDX, Ramintek) and large pharma companies (Farmak).
Alexandra is currently completing an MSc in Medical Parasitology at the London School of Hygiene and Tropical Medicine, following an undergraduate degree in Genetics at Aberystwyth University where she graduated with first-class honours. Her research predominantly utilises molecular interactions and dynamics simulations focusing on the structural modelling of helminth proteins and their potential application as a treatment for autoimmune conditions. She also completed a couple of research and clinical internships across the EU and the UK, including a year’s employment as a diagnostic laboratory technician and the position of a data analyst for NHS Wales.
Romana completed her MSc degree in Biochemistry at Comenius University in Bratislava, where she studied the mechanisms of antibiotic resistance of M. tuberculosis. In her work, she acquired a wide suite of experimental skills with proteins, such as optimising their production in a range of microbial species, isolation using affinity chromatography and activity assays.
Dominika earned her MSc degree in Genetics at Comenius University in Bratislava while working on analysing the telomerase complex of the non-conventional yeasts. Her undergraduate work focused on characterising the metabolism of a lesser-known marine protist D. papillatum.
Katarina received her MSc in Physiology and Ethology from Comenius University in Bratislava, where she is currently pursuing her PhD in Pharmacology. Her research focuses on evaluating plant-based substances with strong antioxidant capacity in animal models of chronic autoimmune disorders with the aim of broadening the current rheumatoid arthritis treatment with the usage of natural compounds. In her prior research, she studied the modulation of gene expression for the renin-angiotensin system alternative pathways in obesity.
Vikram received his BS and MS in Molecular Biophysics and Biochemistry from Yale University where he graduated magna cum laude and defended his structural biology thesis on DNA repair. He is currently a third-year student in the MD/PhD program at Baylor College of Medicine in Houston, Texas, where he is pursuing his PhD in quantitative and computational biology.
Canran received her BS in Biomedical Science from Shanghai Jiao Tong University, where she graduated with first-class honours. She is currently pursuing a PhD degree in Medical Engineering at the California Institute of Technology with a research focus on developing wearable bioelectronics for chronic disease management. She has 18 publications with 7 of them as first/co-first author in the biomedical engineering field. Prior to the graduate program, she worked as an analyst for a healthcare investment bank in China and completed over $80mn overall in fundraising deals for biotech and biopharma startups. She is interested in promoting the clinical translation and commercialisation of biotechnology.
Kazimir is currently a research assistant at the Francis Crick Institute, London. He is using switchable c-MYC mouse models to understand the relationships between cancer and wound healing. Kazimir completed an integrated Masters in Natural Sciences at the University of Cambridge, Biochemistry. Following this, he won a gold medal at iGEM, a global synthetic biology competition. In September 2023, he will be starting a prestigious rotation-based MRC DTP PhD at the University College London-Birkbeck in Experimental and Translational Medicine.
The future potential of mRNA therapeutics and vaccines is constrained by legacy manufacturing methods.
Sensible accelerates the development of the next generation of mRNA medicines by producing non-immunogenic, pure, and highly functional mRNA. We are building a novel mRNA manufacturing paradigm to establish critical biomanufacturing infrastructure for global biosecurity.
Today, mRNA is made via In Vitro Transcription. By leveraging our best-in-class platform, we produce pure, non-immunogenic, high quality mRNA in a rapid and scalable fashion.
long mRNA opens the path towards novel mRNA-based modalities
naturally modified mRNA increases the efficacy of mRNA therapies
cost-effective mRNA manufacturing improves access to mRNA technology
scalable mRNA production strengthens biosecurity and supply chain resilience
We are combining principles of cell engineering, computational biology and precision fermentation to build the cell-based platform for the manufacturing and design of mRNA vaccines and therapeutics.
Our team brings together leading experts in mRNA manufacturing and synthetic biology, with the support of top life science executives and investors.
We are hiring synthetic biologists, bioprocess engineers, mRNA Quality Control analysts and RNA computational biologists. You can drop us an email including your CV or resumé.
United States
Sensible Biotechnologies, Inc.
45 Prospect Street
Cambridge
MA 02139
United Kingdom
Sensible Biotechnologies Limited
Oxford Brookes Bioinnovation Hub
Headington Campus
Oxford OX3 0BP
Slovakia
Sensible Biotechnologies, s.r.o.
Slovak Academy of Sciences
Dubravska cesta 9
Bratislava 845 05
.png)
.png)
